US 11,730,171 B2
Composition for enhancing breast milk component
Hirohisa Izumi, Kanagawa (JP); Tatsuya Ehara, Kanagawa (JP); Akari Hiraku, Kanagawa (JP); Mai Murata, Kanagawa (JP); and Noriyuki Iwabuchi, Kanagawa (JP)
Assigned to Morinaga Milk Industry Co., Ltd., Tokyo (JP)
Appl. No. 16/982,351
Filed by MORINAGA MILK INDUSTRY CO., LTD., Tokyo (JP)
PCT Filed Mar. 25, 2019, PCT No. PCT/JP2019/012602
§ 371(c)(1), (2) Date Sep. 18, 2020,
PCT Pub. No. WO2019/182160, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 2018-056597 (JP), filed on Mar. 23, 2018.
Prior Publication US 2021/0106017 A1, Apr. 15, 2021
Int. Cl. A61K 35/745 (2015.01); A23C 9/152 (2006.01); A23L 33/135 (2016.01); A61K 38/21 (2006.01)
CPC A23C 9/152 (2013.01) [A23L 33/135 (2016.08); A61K 35/745 (2013.01); A61K 38/21 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of enhancing a breast milk component in a pregnant or lactating woman in need thereof, the method comprising a step of administering a composition comprising a therapeutically effective amount of Bifidobacterium breve to the woman; wherein the composition optionally further comprises a therapeutically effective amount of a bacterium of the species Bifidobacterium longum, wherein the breast milk component is selected from the group consisting of a heat-shock protein, a chemokine, an interferon, a lectin, and combinations thereof.